First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two
Days of FDA Approval
ATLANTA, April 24 /PRNewswire/ -- UCB announced today the launch of its CIMplicity(TM) program, designed to enhance treatment support for patients suffering from moderate to severe Crohn's disease. CIMplicity(TM) provides Cimzia(R) patients and their caregivers with comprehensive financial, administrative, compliance and treatment support. The U.S. Food and Drug Administration (FDA) approved Cimzia(R) for adult patients with moderate to severe Crohn's disease who have an inadequate response to conventional therapy on April 22, 2008.
"CIMplicity(TM) was developed by UCB to enhance the Crohn's patient experience by providing comprehensive treatment support to patients receiving Cimzia(R)," said David Robinson, vice president and general manager, UCB. "With the introduction of CIMplicity(TM), our goal is to eliminate some of the issues patients face when managing the treatment of a complex and debilitating condition."
Accelerating Access to Treatment
Just two days after approval, David Rubin, M.D. co-director of the Inflammatory Bowel Disease Center at the University of Chicago Medical Center, administered the first dose of Cimzia(R) and enrolled the first patient, Donna Bynes, in the CIMplicity(TM) program. Bynes, a 29-year old nurse from the Chicago suburbs, diagnosed with Crohn's at age 12, has had to discontinue a number of Crohn's medications over the years for a variety of reasons. Bynes received the first dose of Cimzia(R) in Dr. Rubin's clinic and, as part of the CIMplicity(TM) program, will receive the next three doses through the Cimzia(R) free trial program. Through CIMplicity(TM), Bynes also has the option of having Cimzia(R) shipped directly to her home to be administered by a licensed home health nurse, at no additional cost to her.
"Crohn's disease is a chronic condition often diagnosed in youn
Copyright©2008 PR Newswire.
All rights reserved